Melanotan II pharmacokinetics: half-life, delivery and the practical implications
A close reading of the Melanotan II evidence, without the marketing layer.
ResearchAlso known as: MT-2
A non-selective melanocortin agonist that drives melanogenesis, with a well-documented adverse-effect profile and no approval anywhere.
Melanotan II is classified as a non-selective melanocortin agonist. Its current development status is: never approved; research use only. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.
The Peptide Institute tracks Melanotan II because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Independent Testing
Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.
97.2% average purity across 2 samples
Purity & Testing 99 Transparency 90 Samples 2 91 View company97.6% average purity across 1 sample
Purity & Testing 89 Transparency 52 Samples 1 70 View companyImmunogenicity and stability profile of Melanotan II
Adds to the Melanotan II evidence base without resolving the central question of human efficacy.
Laboratory verification of Melanotan II products across the companies we index.
A close reading of the Melanotan II evidence, without the marketing layer.
Research3 independently tested samples across 2 companies, and what the results say about Melanotan II.
Study SummaryPurity across our Melanotan II samples ranged from 97% to 97.6%. Here is the context.
NewsFree download
What peptides are, why people are using them, and what results people are talking about, in plain English. Sign up and we email you the Playbook right away.